COMP <GO>
BVS vs NVCR // ENTERPRISE SCALE & MARKET CAP
Bioventus Inc. (Class A) (NASDAQ) VS. NovoCure Limited (NASDAQ) • 15-METRIC TALLY: BVS 7
— NVCR 3
▲ ENTERPRISE SCALE & MARKET CAP LEADER: NVCR
LAST: $13.33 (-10.39%) • MKT CAP: $1.25B
market-cap
$1.25B
LAST: $13.15 (+0.31%) • MKT CAP: $1.53B
market-cap
$1.53B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BVS VS. NVCR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BVS | NVCR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 68.30% | 74.50% | -6.20 | NVCR | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 10.40% | -27.50% | +37.90 | BVS | /roic <GO> |
| EV/EBITDA & P/E Valuation | 26.3x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 5.77% | -4.96% | +10.73 | BVS | /fcf-yield <GO> |
| Operating Margin | 9.50% | -23.50% | +33.00 | BVS | /operating-margins <GO> |
| Net Profit Margin | 4.00% | -20.80% | +24.80 | BVS | /net-margins <GO> |
| Revenue Growth (YoY) | -0.90% | 8.30% | -9.20 | NVCR | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.25 | 0.54 | +1.71 | BVS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 6/9 | +1.00 | BVS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.4 | 33.8 | +23.60 | BVS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 51.2x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $1.25B | $1.53B | -$276.2M | NVCR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BVS REV | NVCR REV | BVS GROSS % | NVCR GROSS % | BVS FCF | NVCR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $568.1M | $655.4M | 68.3% | 74.5% | $72.1M | -$75.7M |
| FY 2024 | $573.3M | $605.2M | 67.7% | 77.3% | $37.8M | -$69.2M |
| FY 2023 | $512.3M | $509.3M | — | — | $15.3M | -$73.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BVS // BETA —
NVCR // BETA —